If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJudges Scientific Regulatory News (JDG)

Share Price Information for Judges Scientific (JDG)

Share Price is delayed by 15 minutes
Get Live Data
4,880.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 70.00 (1.434%)
Market Cap: £325.04m
JDG Live PriceLast checked at - London Stock Exchange

Intraday Judges Scientific Share Chart

Director/PDMR Shareholding

29 Oct 2012 14:22

RNS Number : 7756P
Judges Scientific PLC
29 October 2012
 



29 October 2012

Judges Scientific plc (the "Company")

Director/PDMR Shareholding

 

 

Judges Scientific plc announces transactions by directors and others in the shares of the Company as follows:

 

Alex Hambro (the Company Chairman) has today given the requisite 30-day notice to convert 200,000 Convertible Redeemable shares, the entirety of his remaining holding of shares of this class, into 25,489 new Ordinary shares of 5p each ("Ordinary Shares"). The amount payable by him to the Company in respect of the conversion is £22,214. In anticipation of the allotment of these 25,489 new Ordinary shares, he has today sold 15,489 of his existing Ordinary Shares at 860p per share. Following the completion of these transactions, he will no longer hold any Convertible Redeemable shares and his interests in Ordinary Shares will increase to 110,000 shares representing 2.1% of the issued share capital of that class as increased by all the transactions set out in this announcement.

 

Ralph Elman (a non-executive Director) has given the requisite 30-day notice to convert 52,083 Convertible Redeemable shares into 6,638 new Ordinary Shares. The amount payable by him to the Company in respect of the conversion is £5,785. Following the completion of this transaction, he will retain (through his SIPP) an interest in 208,333 Convertible Redeemable shares, representing the entirety of the shares of this class then outstanding, and his interests in Ordinary Shares will increase to 82,429 shares representing 1.6% of the issued share capital of that class as increased by all the transactions set out in this announcement.

 

David Barnbrook (Chief Operating Officer) has given the requisite 30-day notice to convert 52,083 Convertible Redeemable shares into 6,638 new Ordinary Shares. The amount payable by him to the Company in respect of the conversion is £5,785. In anticipation of the allotment of these 6,638 new Ordinary shares, he has today sold 1,720 of his existing Ordinary Shares at 860p per share. Following the completion of these transactions, he will no longer hold any Convertible Redeemable shares and his interests in Ordinary Shares will increase to 20,248 shares representing 0.4% of the issued share capital of that class as increased by all the transactions set out in this announcement. In addition, he holds options over 55,000 Ordinary Shares under the Company's Share Option Plans.

 

Ralph Cohen (Finance Director) has today exercised options over 8,900 new Ordinary Shares under the Company's Approved Share Option Scheme. He has also given the requisite 30-day notice to convert 52,083 Convertible Redeemable shares into 6,638 new Ordinary Shares. The amount payable by him to the Company in respect of the conversion is £5,785. The new Ordinary Shares arising from this conversion and the above exercise of options will be registered in the name of his wife, Mrs Morwenna Rosemary Cohen. Following the completion of these transactions, he will no longer hold any Convertible Redeemable shares and his interests in Ordinary Shares will amount to 50,728 shares representing 1.0% of the issued share capital of that class as increased by all the transactions set out in this announcement. In addition, he holds remaining options over 43,100 Ordinary Shares under the Company's Share Option Plans.

 

Other staff members have today exercised options over 6,000 new Ordinary Shares under the Company's Approved Share Option Scheme.

 

Application has been made for the 14,900 new Ordinary Shares issued today to be admitted to AIM and dealings are expected to commence on 5 November 2012; the corresponding application will be made for the shares to be issued at the end of the 30-day notice period on 28 November and dealings are expected to commence on 4 December 2012. The number of Ordinary Shares currently in issue, including those issued today, is 5,253,096. Completion of the conversions of Convertible Redeemable shares announced above will further increase the number in issue to 5,298,498. The number of Convertible Redeemable shares currently in issue is 564,582. Completion of the conversions announced above will reduce the number outstanding to 208,333.

 

Alex Hambro, Chairman of Judges Scientific commented: "The accounting treatment of the Convertible Redeemable shares under IFRS has been a cause of confusion and irritation among our shareholders. I was pleased to announce earlier in the year that a substantial proportion of these shares had been redeemed or converted well in advance of their final conversion date at the end of 2014. The transactions announced today will reduce the number of these shares still further; out of the original 5 million shares, only 208,333 will remain outstanding, these being convertible into 0.5% of the enlarged share capital as compared with 12% originally. Accordingly, the results for 2012 will be the last to reflect any significant distortions relating to the accounting treatment of these shares."

 

 

Enquiries:

Judges Scientific plc

David Cicurel, CEO

01342 323 600

 

Shore Capital

Pascal Keane

Edward Mansfield

020 7408 4090

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBSBDGGDDBGDC
Date   Source Headline
29th Sep 20097:00 amRNSHalf Yearly Report
22nd Sep 20097:00 amRNSNotice of Results
29th Jul 20093:53 pmRNSShare buyback programme
29th Jul 20099:45 amRNSDirector/PDMR Shareholding
28th Jul 20099:55 amRNSHolding(s) in Company
27th Jul 20097:00 amRNSDirector/PDMR Shareholding
24th Jul 20098:38 amRNSDirector/PDMR Shareholding
20th Jul 20097:00 amRNSTrading Statement
2nd Jul 20095:30 pmRNSHolding(s) in Company
18th Jun 200912:54 pmRNSFurther re Acquisition
10th Jun 20097:00 amRNSAcquisition
22nd May 20093:13 pmRNSAGM Statement
30th Apr 20091:54 pmRNSAnnual Financial Report
30th Mar 20097:00 amRNSFinal Results
30th Jan 20099:04 amRNSShare buyback programme
21st Jan 20097:00 amRNSTrading Statement
17th Dec 20082:46 pmRNSDirectorate Change
17th Nov 20087:00 amRNSAcquisition activity
26th Aug 20087:00 amRNSInterim Results
22nd Aug 200810:50 amRNSNotice of Results
15th Jul 20087:00 amRNSTrading Statement
13th Jun 20084:51 pmRNSHolding(s) in Company
13th Jun 20084:25 pmRNSHolding(s) in Company
13th Jun 20083:16 pmRNSHolding(s) in Company
9th Jun 20084:22 pmRNSFurther re Issue of Equity
22nd May 20087:00 amRNSAGM Statement
21st May 20087:00 amRNSIssue of Equity
29th Apr 20087:01 amRNSDirector/PDMR Shareholding
28th Apr 20085:28 pmRNSCirc re. Panel Waiver
28th Mar 20087:01 amRNSFinal Results
25th Mar 20087:01 amRNSFreehold property purchase
29th Jan 20087:00 amRNSPre Close Trading Statement
30th Nov 20077:01 amRNSDirector/PDMR Shareholding
27th Nov 20077:01 amRNSDirector/PDMR Shareholding
4th Oct 20077:01 amRNSDirector/PDMR Shareholding
25th Sep 20071:25 pmRNSGrant of Options/Dir holding
21st Sep 20077:02 amRNSInterim Results
9th Aug 20074:31 pmRNSHolding in Poole Investments
2nd Aug 20074:33 pmRNSCompany Website
21st May 20075:54 pmRNSResult of AGM
23rd Mar 20077:01 amRNSPreliminary Results
16th Mar 20077:00 amRNSNotice of Preliminary Results
9th Jan 20077:00 amRNSTrading Statement
21st Dec 20061:49 pmRNSTotal Voting Rights
7th Nov 20063:12 pmBUSRule 8.3 - Corus Group PLC
27th Oct 20062:29 pmBUSRule 8.3 - Corus Group PLC
26th Sep 20067:03 amRNSInterim Results
22nd Sep 20067:00 amRNSNotice of Results
5th Sep 20067:02 amRNSAcquisition
28th Mar 200612:31 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.